Hong Kong Exchanges and Clearing Limited

FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation

Form Serial Number:

DA20240321E00275

1. Date of relevant event:

05/02/2024
(dd/mm/yyyy)

2. Date when director became aware of the relevant event/ interest in the shares (if later):

21/03/2024
(dd/mm/yyyy)

3. Stock code:

02096

4. Name of listed corporation:

Simcere Pharmaceutical Group Ltd.

5. Class of shares:

Ordinary Shares

6. Number of issued shares in class:

2,609,761,618

7. Name of director (English) as printed on HKID Card/Passport:

(Surname)	WANG
(Other names)	Xi

10. Name of director (Chinese):

王熙

11. Chinese Character Code as printed on HKID Card:

24. Details of relevant event:

Brief description of relevant event

Capacity in which shares were/are held

Number of shares bought/sold or involved

Currency of transaction

On Exchange

Off Exchange

Before relevant event

After relevant event

Highest price (per share)

Average price (per share)

Average consideration (per share)

Consideration code

Long position

1711	Miscellaneous Other (you must briefly describe the relevant event in the Supplementary Information box)

2501	Other (you must describe the capacity in the Supplementary Information box)

2501	Other (you must describe the capacity in the Supplementary Information box)

Short position

25. Total shares in listed corporation immediately before the relevant event:

	Total number of shares	Percentage figure (%)
Long position	1,802,595,668	68.51

26. Total shares in listed corporation immediately after the relevant event:

	Total number of shares	Percentage figure (%)
Long position	1,802,595,668	69.07

27. Capacity in which interests disclosed in Box 26 are held:

Code describing capacity

Number of shares

2101	Beneficial owner

Long position

164,000

2305	Beneficiary of a trust (other than a discretionary interest)

Long position

164,000

2501	Other (you must describe the capacity in the Supplementary Information box)

Long position

1,802,267,668

28. Further information in derivative interests in listed corporation :

Derivatives code

Exercise period (dd/mm/yyyy)

Consideration - if derivatives granted by listed corporation

Number of shares

		Begins	Ends	Currency	Price for grant	Currency	Exercise price	Currency	Price on assignment

29. Further information in relation to interests of children under 18 and/or spouse:

Child/Spouse

Name of child/spouse

Number of shares

Spouse

Ren Jinsheng

Long position

1,802,267,668

30. Further information in relation to interests of corporations controlled by Director:

Name of controlled corporation	Address and place of incorporation	Name of controlling person	% control	Direct interest (Y/N)	Number of shares

31. Further information in relation to interests held by Director jointly with another person:

Name of joint shareholder	Address	Number of shares

32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:

Names of Trust	Address	Status code	Number of shares

33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):

Names of other parties	Address	Number of shares

Total number of shares in which a director is interested under sections 317 and 318

34. Supplementary information:

21,214,000 ordinary shares, repurchased from October 12, 2023 to January 19, 2024, were cancelled on February 05, 2024,after which,the percentage of shareholding of Ms. Wang Xi was increased from 68.51% to 69.07%. Ms. Wang (i)directly holds 164,000 shares;(ii)is interested in 164,000 shares underlying the RSUs granted to her;and(iii)is interested in 1,802,267,668 shares directly and indirectly held by her spouse (Mr. Ren Jinsheng) together with parties deemed to be persons acting in concert.

35. Log/Serial Number of the previous form:

36. Number of concert party document(s) under section 317 attached/uploaded:

Date of filing this Form 3A:

21/03/2024
(dd/mm/yyyy)